A randomized trial of tenecteplase versus alteplase for acute ischemic stroke

New England Journal of Medicine

Volumn 366, Issue 12, 2012, Pages 1099-1107

  Parsons, Mark ^a   Spratt, Neil ^a   Bivard, Andrew ^a   Campbell, Bruce ^b   Chung, Kong ^a   Miteff, Ferdinand ^a   O'Brien, Bill ^a   Bladin, Christopher ^c   McElduff, Patrick ^a   Allen, Chris ^a   Bateman, Grant ^a   Donnan, Geoffrey ^b   Davis, Stephen ^b   Levi, Christopher ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TENECTEPLASE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PERFUSION; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; STROKE;

EID: 84858685702     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1109842     Document Type: Article

References (22)

1. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695-703.
2. Neumann-Haefelin T, du Mesnil de Rochemont R, Fiebach JB, et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke 2004;35:109-14. (Pubitemid 38057601)
3. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002;41:1229-45. (Pubitemid 36026764)
4. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607-12. (Pubitemid 40344164)
5. Haley EC Jr, Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41:707-11.
6. Parsons MW, Miteff F, Bateman GA, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009;72: 915-21.
7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
8. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
9. Parsons MW, Pepper EM, Chan V, et al. Perfusion computed tomography: prediction of final infarct extent and stroke outcome. Ann Neurol 2005;58:672-9. (Pubitemid 41552542)
10. Wintermark M, Albers GW, Alexandrov AV, et al. Acute stroke imaging research roadmap. Stroke 2008;39:1621-8.
11. Parsons MW, Pepper EM, Bateman GA, Wang Y, Levi CR. Identification of penumbra and infarct core on hyperacute non-contrast and perfusion CT. Neurology 2007;68:730-6. (Pubitemid 46667897)
12. Bivard A, McElduff P, Spratt N, Levi C, Parsons M. Defining the extent of irreversible brain ischemia using perfusion computed tomography. Cerebrovasc Dis 2011;31:238-45.
13. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo- controlled randomised trial. Lancet Neurol 2008;7:299-309.
14. Soares BP, Tong E, Hom J, et al. Reperfusion is a more accurate predictor of follow-up infarct volume than recanalization: a proof of concept using CT in acute ischemic stroke patients. Stroke 2010; 41(1):e34-e40.
15. De Silva DA, Fink JN, Christensen S, et al. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke 2009;40:2872-4.
16. Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, Tomsick T. Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 2005;36:2400-3. (Pubitemid 41566966)
17. Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74.
18. Brown DL, Johnston KC, Wagner DP, Haley EC Jr. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004;35:147-50. (Pubitemid 38057609)
19. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245- 51.
20. Bivard A, Spratt N, Levi C, Parsons M. Perfusion computer tomography: imaging and clinical validation in acute ischaemic stroke. Brain 2011;134:3408-16.
21. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372: 1303-9.
22. Simpson MA, Dewey HM, Churilov L, et al. Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002-2008). Med J Aust 2010;193: 439-43.